Cyclacel Pharmaceuticals Book Value 2011-2026 | CYCC

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Cyclacel Pharmaceuticals

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-2.17 M	607 K	20.4 M	37.3 M	33.3 M	11.7 M	15.3 M	21.8 M	14.3 M	18.8 M	21.7 M	28 M	10 M	19.5 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
37.3 M	-2.17 M	17.9 M

Quarterly Book Value Cyclacel Pharmaceuticals

2025-Q3	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
7.1 M	3.06 M	-2.17 M	-970 K	999 K	-2.21 M	607 K	9.63 M	14.6 M	20 M	26.6 M	30.2 M	33.4 M	37.3 M	41.4 M	43.2 M	48 M	33.3 M	33.3 M	33.3 M	33.3 M	11.7 M	11.7 M	11.7 M	11.7 M	15.3 M	15.3 M	15.3 M	15.3 M	21.8 M	21.8 M	21.8 M	21.8 M	14.3 M	14.3 M	14.3 M	14.3 M	18.8 M	18.8 M	18.8 M	18.8 M	21.7 M	21.7 M	21.7 M	21.7 M	28 M	28 M	28 M	28 M	10 M	10 M	10 M	10 M	19.5 M	19.5 M	19.5 M	19.5 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
48 M	-2.21 M	19.1 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
AbCellera Biologics ABCL	967 M	$ 3.58	0.42 %	$ 1.07 B	Canada
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
AC Immune SA ACIU	112 M	$ 3.22	2.88 %	$ 229 M	Schweiz
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	11.8 M	$ 0.79	-	$ 4.31 M	China
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	54.4 M	-	10.36 %	$ 9.8 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
ADC Therapeutics SA ADCT	88.7 M	$ 4.2	-0.47 %	$ 105 M	Schweiz
argenx SE ARGX	5.5 B	$ 708.98	0.81 %	$ 25 B	Niderland
Ascendis Pharma A/S ASND	-163 M	$ 231.11	0.03 %	$ 5 B	Danmark
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.45	-4.43 %	$ 8.3 B	Australia
Atea Pharmaceuticals AVIR	275 M	$ 6.02	-0.5 %	$ 491 M	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Arcturus Therapeutics Holdings ARCT	214 M	$ 6.59	-0.6 %	$ 180 M	Israel
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
BioCardia BCDA	-1.6 M	$ 1.29	1.57 %	$ 27.3 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
Anika Therapeutics ANIK	271 M	$ 14.36	-	$ 210 M	USA
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Aptose Biosciences APTO	-4.54 M	-	-45.71 %	$ 1.2 M	Canada
AVEO Pharmaceuticals AVEO	45.9 M	-	-	$ 521 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
BioNTech SE BNTX	19.2 B	$ 91.71	1.29 %	$ 27.2 B	Germany
Aytu BioScience AYTU	124 M	$ 2.64	-	$ 16.6 M	USA
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
Burford Capital Limited BUR	1.66 B	$ 8.17	1.49 %	$ 1.33 B	Britain
Autolus Therapeutics plc AUTL	427 M	$ 1.51	-0.33 %	$ 385 M	Britain
Athira Pharma ATHA	44.8 M	-	-	$ 269 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
AstraZeneca PLC AZN	48.7 B	-	-	$ 96.9 B	Britain
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 3.58	-0.28 %	$ 7.79 B	Israel